.Pharmacolibrary.Drugs.C_CardiovascularSystem.C05X_OtherVasoprotectives.C05XX01_BeperminogenePerplasmid.BeperminogenePerplasmid .Pharmacolibrary.Drugs.C_CardiovascularSystem.C05X_OtherVasoprotectives.C05XX01_BeperminogenePerplasmid.BeperminogenePerplasmid| name: | BeperminogenePerplasmid |
| ATC code: | C05XX01 | route: | intramuscular |
| n-compartments | 1 |
Beperminogene perplasmid is a gene therapy drug consisting of a plasmid DNA vector encoding human hepatocyte growth factor (HGF). It is administered as a regenerative treatment for critical limb ischemia due to peripheral arterial disease to promote angiogenesis. It has been approved for use in Japan but is not widely approved globally.
No published human pharmacokinetic study or PK model exists for beperminogene perplasmid, as it is a gene therapy and not a standard small molecule or protein pharmacokinetic entity. Typical PK parameters do not apply to non-viral plasmid gene therapies. Doses are usually measured by μg of plasmid DNA injected intramuscularly; systemic PK such as absorption, clearance, Vd are not characterized.